PROM is the native token of Prom's network, which operates on Polygon CDK. Recent data shows spot netflow indicating tokens moving onto exchanges, but this does not confirm that holders sold or that sales influenced PROM's price. Additionally, futures open interest reflects open and unsettled positions but does not reveal whether traders expect the token's price to rise or fall. This information highlights market activity without clear signals on price direction.
PROM token market activity is presented here with Pluang's cryptocurrency data as of Oct 23, 2026 23:21 WIB. For readers following major cryptocurrencies, 37 out of 50 rose while 11 fell. Notable movers include COTI at Rp210 with a 7.69% increase and a Pluang order activity of 62% Sell / 38% Buy, BCH at Rp5.164.753 up 4.62% with 27% Sell / 73% Buy, and VET at Rp132 rising 4.43% with balanced order activity. The most notable figure is COTI's 7.69% price gain.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
